Loading clinical trials...
Loading clinical trials...
A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE EFFICACY AND SAFETY OF BOSUTINIB MONOTHERAPY IN JAPANESE ADULT PATIENTS WITH NEWLY DIAGNOSED CHRONIC PHASE CHRONIC MYELOGENOUS LEUKEMIA
Conditions
Interventions
Bosutinib
Locations
21
Japan
Fujita Health University Hospital
Toyoake, Aichi-ken, Japan
Toyohashi Municipal Hospital
Toyohashi, Aichi-ken, Japan
Akita University Hospital
Akita, Akita, Japan
Japanese Red Cross Narita Hospital
Narita, Chiba, Japan
Ehime University Hospital
Toon-shi, Ehime, Japan
Kobe City Medical Center General Hospital
Kobe, Hyōgo, Japan
Start Date
May 15, 2017
Primary Completion Date
March 12, 2019
Completion Date
March 4, 2021
Last Updated
May 19, 2022
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions